Ionis, Akcea just got handed a one-way ticket to the end of the regulatory line as the FDA rejects volanesorsen
Ionis $IONS and its sister organization at Akcea have just been slammed with an unexpected rejection of volanesorsen, their drug for regulating plasma triglyceride for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.